Aquestive Therapeutics’ (AQST) “Outperform” Rating Reiterated at Leerink Partners

Leerink Partners reiterated their outperform rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research note issued to investors on Monday morning, Benzinga reports. The brokerage currently has a $12.00 target price on the stock, up from their prior target price of $10.00.

AQST has been the subject of several other reports. HC Wainwright raised their price objective on shares of Aquestive Therapeutics from $9.00 to $10.00 and gave the stock a buy rating in a report on Monday. JMP Securities reaffirmed a market outperform rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a report on Monday, August 12th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of Buy and an average price target of $8.67.

Aquestive Therapeutics Stock Down 2.3 %

Aquestive Therapeutics stock opened at $4.68 on Monday. Aquestive Therapeutics has a twelve month low of $1.25 and a twelve month high of $6.23. The firm has a 50 day moving average price of $4.31 and a 200-day moving average price of $3.68. The company has a market capitalization of $426.06 million, a P/E ratio of -11.14 and a beta of 2.84.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.08. The company had revenue of $20.10 million for the quarter, compared to the consensus estimate of $12.62 million. During the same period in the prior year, the company earned ($0.10) earnings per share. Equities analysts expect that Aquestive Therapeutics will post -0.47 EPS for the current fiscal year.

Institutional Trading of Aquestive Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AQST. Janney Montgomery Scott LLC purchased a new stake in Aquestive Therapeutics in the 1st quarter worth approximately $1,456,000. SG Americas Securities LLC purchased a new stake in Aquestive Therapeutics in the 1st quarter worth approximately $54,000. Vanguard Group Inc. raised its position in shares of Aquestive Therapeutics by 71.7% during the 1st quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock valued at $13,813,000 after buying an additional 1,353,518 shares in the last quarter. Lazard Asset Management LLC raised its position in shares of Aquestive Therapeutics by 115.5% during the 1st quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock valued at $124,000 after buying an additional 15,601 shares in the last quarter. Finally, Virtu Financial LLC raised its position in shares of Aquestive Therapeutics by 219.7% during the 1st quarter. Virtu Financial LLC now owns 102,836 shares of the company’s stock valued at $438,000 after buying an additional 70,666 shares in the last quarter. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.